Equities
Health CareMedical Equipment and Services
  • Price (USD)46.91
  • Today's Change-0.44 / -0.93%
  • Shares traded529.11k
  • 1 Year change-1.98%
  • Beta1.7677
Data delayed at least 15 minutes, as of Nov 13 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Enovis Corporation is a medical technology company. It is focused on developing clinically differentiated solutions by manufacturing and distributing medical devices with a range of products used for reconstructive surgery, rehabilitation, pain management and physical therapy. It operates through two segments: Prevention & Recovery and Reconstructive. The Prevention & Recovery segment develops, manufactures, and distributes rigid bracing products, orthopedic soft goods, vascular systems and compression garments, and hot and cold therapy products and offers recovery sciences products in the clinical rehabilitation and sports medicine markets, such as bone growth stimulators and electrical stimulators used for pain management. The Reconstructive segment develops, manufactures, and markets a variety of knee, hip, shoulder, elbow, foot, ankle, and finger implant products and surgical productivity tools. It also provides Novastep, a minimally invasive surgery (MIS) foot and ankle solutions.

  • Revenue in USD (TTM)2.00bn
  • Net income in USD-121.38m
  • Incorporated1998
  • Employees6.55k
  • Location
    Enovis Corp2711 CENTERVILLE ROAD, SUITE 400WILMINGTON 19808United StatesUSA
  • Phone+1 (302) 252-9160
  • Fax+1 (301) 323-9001
  • Websitehttps://www.enovis.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
10X Genomics Inc629.74m-182.55m1.92bn1.26k--2.66--3.06-1.53-1.535.265.970.66772.406.72500,193.00-19.36-25.52-21.99-29.0566.6375.88-28.99-48.534.12--0.00--19.8133.43-53.67--49.15--
Integra Lifesciences Holdings Corp1.56bn-6.54m1.96bn3.95k--1.2915.371.25-0.0881-0.088120.2219.730.4011.595.99396,583.90-0.16773.33-0.20023.6859.2963.67-0.41827.990.72614.050.54280.00-1.030.9219-62.482.19-2.97--
Novocure Ltd577.74m-149.78m1.97bn1.45k--5.45--3.41-1.39-1.395.373.340.48793.598.74397,617.30-12.65-7.74-20.29-8.9576.4277.22-25.93-14.691.44--0.6446---5.3015.47-123.75--32.19--
Tandem Diabetes Care Inc854.35m-126.78m2.06bn2.40k--8.66--2.41-1.94-1.9413.083.620.90042.908.23355,979.60-13.36-10.08-17.47-12.2349.7951.77-14.84-11.592.32--0.5945---6.6832.39-135.33--76.81--
Premier Inc1.28bn147.17m2.22bn2.90k16.721.168.461.741.381.3711.6519.980.3562--2.99439,914.103.837.084.788.9567.2461.2910.7616.05----0.277127.320.76842.03-31.70-11.93-2.76--
Omnicell Inc1.06bn-17.69m2.25bn3.66k--1.8433.862.11-0.3917-0.391723.1726.590.47045.904.06291,563.30-0.78171.73-1.112.2541.4446.69-1.662.920.9529--0.31720.00-11.487.82-460.68--0.235--
Conmed Corp1.29bn131.74m2.31bn4.00k17.702.4811.361.804.234.2341.3830.210.5551.715.58322,029.005.680.89726.621.0255.6554.9510.231.651.065.220.5021139.1619.067.68179.9910.042.890.00
LeMaitre Vascular Inc213.03m41.32m2.37bn614.0057.867.1646.5211.131.821.829.4114.730.59921.117.59346,952.8011.629.0212.669.9368.3465.8319.4015.455.52----40.4119.6912.8845.895.9618.9315.51
Warby Parker Inc742.53m-32.56m2.46bn2.14k--7.32216.583.31-0.2731-0.27316.202.801.225.70818.21346,975.20-5.37---6.78--55.3257.49-4.39-14.532.06--0.00--11.9819.6742.75------
UFP Technologies Inc461.85m54.21m2.64bn3.09k49.088.0139.215.717.007.0059.6442.890.88964.186.15149,320.4010.449.6912.0010.9528.3126.3311.7410.141.4313.440.39180.0013.0816.007.5025.7114.08--
Enovis Corp2.00bn-121.38m2.65bn6.55k--0.794318.091.32-2.21-2.1736.4359.610.40231.595.91305,598.20-2.43-0.3569-2.66-0.4156.9648.19-6.03-1.061.120.98890.2876--9.22-4.89-40.29--11.91--
Irhythm Technologies Inc560.03m-150.66m2.78bn2.00k--38.77--4.97-4.85-4.8518.042.290.8312.568.79280,012.50-22.33-21.92-26.27-26.7767.8369.39-26.90-25.756.12-24.180.90--19.9027.32-6.24--50.82--
LivaNova PLC1.24bn23.68m2.81bn2.90k121.642.1541.462.270.42590.425922.8124.130.51192.476.42428,185.900.9777-6.011.12-7.4267.7866.991.91-13.562.872.460.3234--12.890.8278120.34---1.64--
Quidelortho Corp2.83bn-1.86bn2.89bn7.10k--0.9088--1.02-27.79-27.7942.3547.300.3722.589.15399,239.40-24.4011.34-27.5112.9147.8962.71-65.6020.930.79290.78950.44690.00-8.2141.83-101.84--45.87--
TransMedics Group Inc401.09m32.64m2.99bn584.0094.9114.2559.297.460.93890.938911.606.250.54393.565.32686,797.904.43-16.084.78-17.9559.3465.378.14-40.477.33--0.7078--158.5379.3630.92--225.12--
Inari Medical Inc574.50m-78.58m3.12bn1.30k--7.17--5.44-1.35-1.359.907.440.92211.597.46441,921.50-12.61-0.5941-15.24-0.669686.8289.06-13.68-0.62951.40--0.00--28.73135.4094.41--52.46--
Data as of Nov 13 2024. Currency figures normalised to Enovis Corp's reporting currency: US Dollar USD

Institutional shareholders

58.31%Per cent of shares held by top holders
HolderShares% Held
T. Rowe Price Investment Management, Inc.as of 30 Jun 20246.64m11.89%
The Vanguard Group, Inc.as of 30 Jun 20245.28m9.45%
BlackRock Fund Advisorsas of 30 Jun 20244.53m8.12%
Diamond Hill Capital Management, Inc.as of 30 Sep 20243.00m5.38%
Dimensional Fund Advisors LPas of 30 Sep 20242.87m5.14%
Davenport & Co. LLCas of 30 Sep 20242.63m4.70%
Royce & Associates LPas of 30 Sep 20242.40m4.30%
Millennium Management LLCas of 30 Jun 20241.92m3.44%
Channing Capital Management LLCas of 30 Jun 20241.71m3.07%
SSgA Funds Management, Inc.as of 30 Jun 20241.58m2.83%
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.